EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer

Jie Fu, Yi-Dan Yan, Xu Wan, Xiao-Fan Sun, Xiu-Mei Ma, Ying-Jie Su

Frontiers in Pharmacology · 06.01.2025 · 15

DOI: 10.3389/fphar.2024.1516735 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 06.01.2025. Verfasst von Jie Fu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Punan Branch of Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

PD-1/PD-L1 inhibitors are novel immunotherapeutic agents that have been approved for first-line treatment in advanced non-small cell lung cancer (NSCLC). This study aims to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors, which have completed phase 3 clinical trials, as a first-line treatment in patients with advanced NSCLC. Materials and methods A systematic search of PubMed, Embase and the Cochrane Library was performed to extract eligible literature up to October 2023. Findings included overall survival (OS), objective response rate (ORR), progression-free survival (PFS), and grade ≥3 treatment-related adverse events (TRAEs). Furthermore, subgroup analyses were conducted based on PD-L1 expression levels and histological type.

Results

We analyzed 29 studies including 18,885 patients. In analyses of all patients, penpulimab plus chemotherapy led the way for OS (HR 0.55, 95% CI: 0.40–0.75) and PFS (HR 0.43, 95% CI: 0.27–0.67). Regarding OS, for patients with PD-L1 expression ≥50%, 1%–49% and <1%, camrelizumab + chemotherapy (HR 0.48, 95% CI: 0.21–1.11), cemiplimab + chemotherapy (HR 0.50, 95% CI: 0.32–0.79) and nivolumab + ipilimumab (HR 0.64, 95% CI: 0.51–0.81) were considered optimal treatments. Compared with chemotherapy, monotherapy with nivolumab, cemiplimab, pembrolizumab, atezolizumab and durvalumab had lower odds of TRAE grade ≥3.

Conclusion

In all patients, penpulimab plus chemotherapy was the most effective therapy, but treatment preferences varied by PD-L1 expression, histology type and associated outcomes. Safety at the individual patient level must be a high priority in the decision-making process. Further validation is warranted.

Schlagwörter

Stichwörter der Autor:innen

PD-1/PD-L1 inhibitorsimmune checkpoint inhibitorsnetwork meta-analysisnon-small cell lung cancerprogrammed death-ligand 1

Autor:innen und Institutionen

  • Department of Pharmacy, Punan Branch of Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Pharmacy, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Internal Medicine, Punan Branch of Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Internal Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Radiation Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Zitieren

APA

Fu, J., Yan, Y. D., Wan, X., Sun, X. F., Ma, X. M., & Su, Y. J. (2025). A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1516735

Vancouver

Fu J, Yan YD, Wan X, Sun XF, Ma XM, Su YJ. A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer. Frontiers in Pharmacology. 2025;15. doi:10.3389/fphar.2024.1516735

BibTeX
@article{Fu2025,
  author = {Fu, Jie and Yan, Yi-Dan and Wan, Xu and Sun, Xiao-Fan and Ma, Xiu-Mei and Su, Ying-Jie},
  title = {A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fphar.2024.1516735}
}
Kostenlos starten →